Armatus Bio, a Columbus, OH-based biotechnology company developing new vectorized RNAi therapeutics for neuromuscular diseases, received a $3M investment from SOLVE FSHD.
The company intends to use the funds to support ARM-201, its AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic protein responsible for muscle degeneration in individuals with FSHD.
Armatus Bio is a late preclinical stage biotechnology company leveraging vectorized RNAi to address urgent unmet medical needs in genetically-driven neurological diseases. In addition to ARM-201, the company is building a pipeline of precision medicines that can support care for people with other genetic neuromuscular disorders.
FSHD is one of the most common forms of muscular dystrophy, affecting approximately 1 in 8,000 individuals globally.
FinSMEs
06/05/2025